Dennis N. Berman - Jan 3, 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Milton H. Werner, attorney-in-fact
Stock symbol
IKT
Transactions as of
Jan 3, 2025
Transactions value $
$0
Form type
4
Date filed
1/7/2025, 06:38 PM
Previous filing
Jul 18, 2024
Next filing
Feb 19, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +344K $0.00 344K Jan 3, 2025 Common Stock 344K $1.26 Direct F1
transaction IKT Stock Option (Right to Buy) Award $0 +172K $0.00 172K Jan 3, 2025 Common Stock 172K $1.45 Direct F2
transaction IKT Stock Option (Right to Buy) Award $0 +317K $0.00 317K Jan 3, 2025 Common Stock 317K $1.58 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vested and became exercisable on October 9, 2024.
F2 The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.
F3 The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.